Arix Bioscience 대차 대조표 상태

재무 상태 기준 확인 6/6

Arix Bioscience 의 총 주주 지분은 £239.1M 이고 총 부채는 £0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 £240.5M 및 £1.4M 입니다. Arix Bioscience 의 EBIT는 £8.2M 이며 이자보상배율은 -2.4 입니다. £101.0M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

UK£0

부채

이자 보상 비율	-2.4x
현금	UK£100.99m
주식	UK£239.12m
총 부채	UK£1.41m
총 자산	UK£240.53m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: 3HY 의 단기 자산 ( £103.4M )이 단기 부채( £1.4M ).

장기 부채: 3HY 에는 장기 부채가 없습니다.

부채 대 자본 내역 및 분석

부채 수준: 3HY 부채가 없습니다.

부채 감소: 3HY 지난 5년간 부채가 없습니다.

부채 범위: 3HY 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 3HY 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Arix Bioscience 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Investor sentiment improves as stock rises 16%

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought €79k worth of stock

New minor risk - Share price stability

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought €87k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought €243k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Less than half of directors are independent

Independent Non-Executive Chairman recently bought €90k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings released: UK£0.48 loss per share (vs UK£0.97 profit in FY 2020)

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Less than half of directors are independent

Investor sentiment improved over the past week

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day high: €2.36

Executive Chairman recently bought €416k worth of stock

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: €1.82

Market bids up stock over the past week

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: €1.70

New 90-day high: €1.16

New 90-day high - €1.08

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기